Abu Dhabi pharmaceutical manufacturer Neopharma and US-based Elevar Therapeutics have entered into an agreement to establish a joint venture in the UAE. The 50:50 partnership plans to establish a sales network for Rivoceranib, a targeted anti-cancer drug, and also conduct clinical trials for other pipeline candidates. Neopharma said in a statement that it will undertake to commercialise responsibility through its presence in various countries of the MENA region and India. Suresh Kumar Nandiraju, chief operating officer of Neopharma said: “This…